Rocket Pharmaceuticals Reports Key Data, Development Milestones Demonstrated During Danon Disease Investor Webinar For Its Pivotal Phase 2 Study In Participants Treated Under Modified Protocol

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) provided updates during its October 6 investor webinar regarding its pivotal Phase 2 study for Danon disease. The company reported sustained biological activity from longer-term Phase 1 follow-up and initial safety observations in the first three patients treated under a modified protocol. The updates indicate a defined path toward completing the FDA-aligned trial.